Wegovy at its top dose (7.2 mg) produced 20.7% in the STEP UP trial 9
By route of administration, the oral segment is expected to command the highest share in the global anti-obesity drug market with 33.1% in 2026, predominantly because of patient preference and its convenience in daily use
The size of the benefit depends on accurate dosing, careful titration, and body-composition tracking, which is exactly where supervised care separates from a mail-order injection
Using a one-way ANOVA model ( = 0.05, six groups, n = 7 per group equivalent), the observed effect size (Cohens f) was 1.59, corresponding to an value of 0.72
however, it is independent of ER-mediated mechanism in MDA-MB-231 cells (Yaacob et al., 2014)